Inspiring Health

Humira Biosimilar Biosimilars are touted as the future of innovative biologic medicines, offering more affordable treatment options for patients worldwide. However, with the impending patent expiry of blockbuster drugs like Humira, there are still many unanswered questions about how the biosimilar market will evolve. What are biosimilars? Biosimilars are biologic medicines that are developed to be similar to an existing approved biologic drug, known as the reference product. They are engineered to be highly similar to the original biologic in terms of quality characteristics, biological activity, safety and efficacy. However, biosimilars are not generic copies of biologics. Developing a biosimilar is more challenging than a generic small molecule drug due to the complexity of biologics which are produced through living systems. Stringent regulatory requirements need to be fulfilled to demonstrate biosimilarity. The first Humira biosimilar Humira (adalimumab) developed by AbbVie i...

SNP Genotyping and Analysis Single nucleotide polymorphisms or SNPs are the most common genetic variations among individuals. With the advancement of next-generation sequencing technologies, SNP genotyping has become a powerful tool for studying human genetics and discovering disease-associated variants. Introduction to SNP Genotyping A SNP occurs when a single nucleotide differs between members of the same species or between paired chromosomes in an individual. SNPs make up over 90% of all human genetic variation. By comparing SNPs in DNA samples from many individuals, researchers can map genetic variations associated with traits and disease susceptibilities. There are several high-throughput methods available today for identifying SNPs across the human genome at an unprecedented scale and resolution. Microarray-based Genotyping One of the earliest and most widely used SNP genotyping platforms is microarray-based hybridization assays. In this approach, DNA samples are amplified an...